Figure 12

![Figure 12: Dose-response data for Bifidobacterium breve CCFM683 at different colony-forming unit levels in an imiquimod-induced psoriasis mouse model. Higher doses of 10^9 and 10^10 CFU per day demonstrated more substantial reductions in skin inflammation markers including keratin 16, keratin 17, and pro-inflammatory cytokines.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143451/bin/nutrients-15-01952-g012.jpg)

> Source: Xinqi Chen et al. "Dose-Response Efficacy and Mechanisms of Orally Administered Bifidobacterium bre." *Nutrients*, 2023. PMID: [37111171](https://pubmed.ncbi.nlm.nih.gov/37111171/)

<figure>
  <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143451/bin/nutrients-15-01952-g012.jpg" alt="Dose-response data for Bifidobacterium breve CCFM683 at different colony-forming unit levels in an imiquimod-induced psoriasis mouse model. Higher doses of 10^9 and 10^10 CFU per day demonstrated more substantial reductions in skin inflammation markers including keratin 16, keratin 17, and pro-inflammatory cytokines." />
  <figcaption>Figure 12. Dose-response data for Bifidobacterium breve CCFM683 at different colony-forming unit levels in an imiquimod-induced psoriasis mouse model. Higher doses of 10^9 and 10^10 CFU per day demonstrated more substantial reductions in skin inflammation markers including keratin 16, keratin 17, and pro-inflammatory cytokines.<br>  Source: Xinqi Chen et al. "Dose-Response Efficacy and Mechanisms of Orally Administered Bifidobacterium bre." <em>Nutrients</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37111171/">37111171</a></figcaption>
</figure>